This biological process, where mature, specialized cells lose their distinct characteristics and revert to a more primitive, aggressive state, is a universally recognized sign of poor prognosis across ...
Adding a PD-1 inhibitor to standard of care improved disease-free survival (DFS) in stage III soft-tissue sarcoma of the extremity, a randomized trial showed. In patients with mostly undifferentiated ...
The Role of Irradiation of the Internal Mammary Lymph Nodes in High-Risk Stage II to IIIA Breast Cancer Patients After High-Dose Chemotherapy: A Prospective Sequential Nonrandomized Study Purpose: The ...
Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the limb significantly improved disease-free survival, according to the results ...
This retrospective cohort study of limb-sparing eSTS resections integrated clinical variables and radiomic features, including eSTS and limb dimensions. Target outcomes included surgical site ...
Socioeconomic and demographic factors impact surgical outcomes in upper extremity soft tissue sarcomas, affecting amputation rates and overall survival. Hispanic/Latino patients presented with larger ...
In part 3 of an interview, MD Anderson’s Ravin Ratan, MD, MEd, discusses neoadjuvant immune checkpoint blockade for 2 specific types of soft tissue sarcomas. Liposarcomas originate in fat cells and ...
Letetresgene autoleucel (lete-cel) showed a 42% response rate in a phase 2 trial for synovial sarcoma and myxoid/round cell liposarcoma. The trial included 64 patients, with 41% response in synovial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results